{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:26:56Z","timestamp":1760956016697,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.biologicals.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:09:35Z","timestamp":1579306175000},"page":"28-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Acidic isoforms of Erwinase form part of the product: Correlation with clinical experience"],"prefix":"10.1016","volume":"64","author":[{"given":"David","family":"Gervais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2020.01.005_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nyas.12496","article-title":"Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia","volume":"1329","author":"Salzer","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.biologicals.2020.01.005_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukaemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biologicals.2020.01.005_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E coli aspraginase in children with acute lymphoblastic leukaemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.biologicals.2020.01.005_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","article-title":"Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients","volume":"17","author":"Wang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.biologicals.2020.01.005_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10238-008-0026-9","article-title":"The cross\u2010reactivity of anti\u2010asparaginase antibodies against different l\u2010asparaginase preparations","volume":"9","author":"Zalewska\u2010Szewczyk","year":"2009","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.biologicals.2020.01.005_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00449-012-0802-5","article-title":"Validation of a 30-year-old process for the manufacture of L-asparaginase from Erwinia chrysanthemi","volume":"36","author":"Gervais","year":"2013","journal-title":"Bioproc Biosyst Eng"},{"key":"10.1016\/j.biologicals.2020.01.005_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpba.2017.03.004","article-title":"Robust quantitation of basic-protein higher-order aggregates using size-exclusion chromatography","volume":"139","author":"Gervais","year":"2017","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.biologicals.2020.01.005_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jbiotec.2006.07.037","article-title":"L-Asparaginase from Erwinia chrysanthemi 3937: cloning, expression and characterization","volume":"127","author":"Kotzia","year":"2007","journal-title":"J Biotechnol"},{"issue":"17","key":"10.1016\/j.biologicals.2020.01.005_bib9","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1111\/j.1742-4658.2008.06574.x","article-title":"Structural and functional insights into Erwinia carotovora l\u2010asparaginase","volume":"275","author":"Papageorgiou","year":"2008","journal-title":"FEBS J"},{"key":"10.1016\/j.biologicals.2020.01.005_bib10","doi-asserted-by":"crossref","first-page":"17664","DOI":"10.1074\/jbc.M116.728485","article-title":"Design and characterisation of Erwinia chrysanthemi L-asparaginase variants with diminished L-glutaminase activity","volume":"291","author":"Nguyen","year":"2016","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.biologicals.2020.01.005_bib11","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/bi0029595","article-title":"Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase","volume":"40","author":"Aghaiypour","year":"2001","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.biologicals.2020.01.005_bib13","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1007\/s11095-015-1722-2","article-title":"Structural characterisation of non-deamidated acidic variants of Erwinia chrysanthemi L-asparaginase using small-angle X-ray scattering and ion-mobility mass spectrometry","volume":"32","author":"Gervais","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.biologicals.2020.01.005_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ab.2014.08.004","article-title":"Capillary isoelectric focusing of a difficult-to-denature tetrameric enzyme using alkylurea\u2013urea mixtures","volume":"465","author":"Gervais","year":"2014","journal-title":"Anal Biochem"},{"key":"10.1016\/j.biologicals.2020.01.005_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.enzmictec.2016.12.003","article-title":"Understanding the process-induced formation of minor conformational variants of Erwinia chrysanthemi l-asparaginase","volume":"98","author":"Gervais","year":"2017","journal-title":"Enzym Microb Technol"},{"issue":"1","key":"10.1016\/j.biologicals.2020.01.005_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci"},{"issue":"3","key":"10.1016\/j.biologicals.2020.01.005_bib17","article-title":"The batch production of L-asparaginase from Erwinia carotovora","volume":"65","author":"Buck","year":"1971","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.biologicals.2020.01.005_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/00224065.1986.11978984","article-title":"Process capability indices","volume":"18","author":"Kane","year":"1986","journal-title":"J Qual Technol"},{"issue":"4","key":"10.1016\/j.biologicals.2020.01.005_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-1638(199907\/08)15:4<321::AID-QRE258>3.0.CO;2-5","article-title":"Making decisions in assessing process capability index C-pk","volume":"15","author":"Pearn","year":"1999","journal-title":"Qual Reliab Eng Int"},{"key":"10.1016\/j.biologicals.2020.01.005_bib20","series-title":"Introduction to statistical quality control","first-page":"776","author":"Montgomery","year":"2004"},{"issue":"4","key":"10.1016\/j.biologicals.2020.01.005_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biologicals.2020.01.005_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.25757","article-title":"Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. Coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia","volume":"63","author":"Vrooman","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.biologicals.2020.01.005_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/1097-0142(197208)30:2<376::AID-CNCR2820300212>3.0.CO;2-4","article-title":"Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli","volume":"30","author":"Ohnuma","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.biologicals.2020.01.005_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.1999.01192.x","article-title":"Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL\/NHL-BFM treatment protocols","volume":"104","author":"Pinheiro","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biologicals.2020.01.005_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/mpo.2950180612","article-title":"Non\u2010randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia","volume":"18","author":"Eden","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.biologicals.2020.01.005_bib27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pbc.24938","article-title":"Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate\u2010use trial","volume":"61","author":"Plourde","year":"2014","journal-title":"Pediatr Blood Cancer"},{"first-page":"7","year":"1999","series-title":"International conference on harmonisation, specifications: test procedures and acceptance criteria for biotechnological\/biological products. Q6B","key":"10.1016\/j.biologicals.2020.01.005_bib28"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105620300154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105620300154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:13:36Z","timestamp":1760922816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105620300154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":26,"alternative-id":["S1045105620300154"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.01.005","relation":{},"ISSN":["1045-1056"],"issn-type":[{"type":"print","value":"1045-1056"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acidic isoforms of Erwinase form part of the product: Correlation with clinical experience","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}